Header Logo

Connection

Jeffrey Borgia to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Jeffrey Borgia has written about Lung Neoplasms.
Jeffrey Borgia
Connection Strength
8.208
Lung Neoplasms
  1. Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy. J Cachexia Sarcopenia Muscle. 2024 Dec; 15(6):2311-2322.
    View in: PubMed
    Score: 0.662
  2. Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules. Clin Chim Acta. 2022 Oct 01; 535:197-202.
    View in: PubMed
    Score: 0.575
  3. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
    View in: PubMed
    Score: 0.553
  4. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
    View in: PubMed
    Score: 0.513
  5. Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
    View in: PubMed
    Score: 0.424
  6. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.422
  7. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
    View in: PubMed
    Score: 0.418
  8. Reply. Ann Thorac Surg. 2018 07; 106(1):316-317.
    View in: PubMed
    Score: 0.415
  9. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
    View in: PubMed
    Score: 0.408
  10. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
    View in: PubMed
    Score: 0.349
  11. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.332
  12. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
    View in: PubMed
    Score: 0.331
  13. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
    View in: PubMed
    Score: 0.294
  14. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
    View in: PubMed
    Score: 0.288
  15. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.269
  16. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.253
  17. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.251
  18. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
    View in: PubMed
    Score: 0.247
  19. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.225
  20. A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Mol Cancer. 2024 Nov 06; 23(1):247.
    View in: PubMed
    Score: 0.167
  21. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020 10 01; 80(19):4224-4232.
    View in: PubMed
    Score: 0.124
  22. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Res. 2019 09 01; 79(17):4439-4452.
    View in: PubMed
    Score: 0.115
  23. Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening. BMC Genomics. 2018 Jul 20; 19(1):545.
    View in: PubMed
    Score: 0.108
  24. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.098
  25. Rac1-mediated cytoskeleton rearrangements induced by intersectin-1s deficiency promotes lung cancer cell proliferation, migration and metastasis. Mol Cancer. 2016 09 14; 15(1):59.
    View in: PubMed
    Score: 0.095
  26. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
    View in: PubMed
    Score: 0.092
  27. PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer. J Biol Chem. 2015 May 22; 290(21):13479-89.
    View in: PubMed
    Score: 0.086
  28. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 2013 Jul 16; 12:76.
    View in: PubMed
    Score: 0.076
  29. Kernelized partial least squares for feature reduction and classification of gene microarray data. BMC Syst Biol. 2011; 5 Suppl 3:S13.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.